WO2005102276A1 - Antimicrobial compositions - Google Patents

Antimicrobial compositions Download PDF

Info

Publication number
WO2005102276A1
WO2005102276A1 PCT/US2005/008370 US2005008370W WO2005102276A1 WO 2005102276 A1 WO2005102276 A1 WO 2005102276A1 US 2005008370 W US2005008370 W US 2005008370W WO 2005102276 A1 WO2005102276 A1 WO 2005102276A1
Authority
WO
WIPO (PCT)
Prior art keywords
cfu
cepacia
albicans
niger
aeruginosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/008370
Other languages
French (fr)
Inventor
John J. Merianos
Paul Garelick
Susan M. Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISP Investments LLC
Original Assignee
ISP Investments LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35061391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005102276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ISP Investments LLC filed Critical ISP Investments LLC
Priority to AU2005235136A priority Critical patent/AU2005235136B2/en
Priority to EP05728244.4A priority patent/EP1734922B1/en
Priority to BRPI0509652-9A priority patent/BRPI0509652B1/en
Priority to JP2007507324A priority patent/JP2007532542A/en
Priority to ES05728244T priority patent/ES2422897T3/en
Priority to CA2560010A priority patent/CA2560010C/en
Priority to PL05728244T priority patent/PL1734922T3/en
Publication of WO2005102276A1 publication Critical patent/WO2005102276A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to antimicrobial compositions, and, more particularly, to a defined blend of a 1,2-diol and phenoxyethanol, optionally with a co-biocide, which compositions show broad activity against bacteria, fungi and mold spores.
  • Personal care products come in many different forms. They include creams, lotions, pastes, liquids, aerosols, shampoos, gels, wipes, bars, sticks, powders and granules any or all of which are intended for topical application to the skin including the scalp and the mucosa including the lips.
  • the products are generally designed to have a substantial shelf life. The products need to be manufactured at one site, transported possibly over a considerable distance to a depot or other storage facility prior to further transport to a point of sale. The product may then spend considerable time on a retailer's shelf prior to purchase and further storage by the user whether for individual use or use in, for example, a hotel, workplace, institution or the like. All of such storage will take place under uncontrolled conditions including considerable variation in temperature.
  • IPBC iodopropynyl butyl carbamate
  • PE phenoxyethanol
  • U.S. Pat. 5,516,510 also disclosed deodorizing active ingredients to reduce the unpleasant odor caused by microorganisms which comprised a glycerin monoalkyl ether in combination with an astringent and/or a naturally occurring deodorant.
  • EP 1206933 described a preservative composition of caprylyl glycol (1,2-octanediol) and iodopropynyl butyl carbamate in a weight ratio of 0.1 to 500.
  • U.S. Pat. 5,733,362 was directed to a bacterial composition of 2-methyl-4,5- trimethylene-4-isothiazoline-3-on; 3-iodo-2-propynyl butyl carbamate and 2-phenoxyethanol .
  • EP 1238651 described that the activity of preservative mixtures of iodopropynyl butyl carbamate and phenoxyethanol, in a weight ratio of 1 :90 to 1 :200, preferably 1 :100, can be potentiated by adding caprylyl glycol thereto, in a weight ratio of the latter to the mixture of 0.1 to 500, preferably 1 :55.
  • the formulation of caprylyl glycol, iodopropynyl butyl carbamate and phenoxyethanol had weight ratios of each of 55: 1 : 100 to 200:1 :400, respectively.
  • the personal care formulations contained 0.1-30% caprylyl glycol, preferably 0.5%; with 0.001-1% IPBC, preferably 0.001-0.01%; and with phenoxyethanol of 0.1-3%, preferably 0.5-1%.
  • JP Application No. 11045504 described an antiseptic microbicide and compositions thereof which contained a 1,2-alkane diol. These compositions effectively reduced the required dosage of conventional antiseptic microbicides such as paraben, benzoic acid and the like.
  • the 1,2-alkane diol therein could be blended with a photosensitizer, benzoic acid or its salt, phenoxyethanol or 4-isopropyl-3-methylphenol.
  • suitable blends of 1,2-alkane diol and phenoxyethanol at predetermined weight ratios and HLB values, which could deliver water insoluble biocides such as IPBC into aqueous personal care systems at a relatively high concentration of such biocides.
  • an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt.
  • a preferred antimicrobial composition of the invention includes (c) sorbic acid and/or 1 % iodopropynyl butyl carbamate. Most preferred antimicrobial compositions herein are those wherein (a) is about 44% and (b) is about 56%. Also preferred are antimicrobial compositions wherein (c) is sorbic acid present in an amount of about 5-7% of the composition, or IPBC present in an amount of 1.25-1.50%.
  • Preferred antimicrobial compositions of the invention include those wherein (a) is 41-42%), (b) is 52-53%; and (c) is sorbic acid 5-7%; and (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.
  • the invention also encompasses personal care products which include the antimicrobial composition described above, preferably wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably 0.5-1.5%.
  • an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt.
  • the antimicrobial composition includes (c) sorbic acid and/or 1% iodopropynyl butyl carbamate.
  • the antimicrobial composition includes (a) about 44% and (b) about 56%, and, optionally, (c) is sorbic acid, present in an amount of about 5-7% of the composition, or (c) is IPBC present in an amount of 1.25-1.50%.
  • it is an antimicrobial composition wherein (a) is 41-42%, (b) is 52-53%>; and (c) is sorbic acid 5-7%; most preferably, wherein (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.
  • Personal care products particularly utilize the antimicrobial composition, preferably, wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably, 0.5-1.5%).
  • the invention will now be described in more detail by the following challenge test examples on the invention formulations.
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
  • PRODUCT BASE Screening Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1 ,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
  • PRODUCT BASE Screening Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1 ,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
  • PRODUCT BASE Screening Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60) / 2.5% BIT
  • PRODUCT BASE Screening Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60) / 2.5% BIT
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1 ,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
  • PRODUCT BASE Nonionic Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
  • PRODUCT BASE Nonionic Emulsion
  • PRODUCT BASE Screening Emulsion
  • PRODUCT BASE Screening Emulsion
  • PRODUCT BASE Nonionic Emulsion
  • PRODUCT BASE Screening Emulsion
  • ANTIMICROBIAL 1,2-Octanediol/Phenoxyethanol (40/60), 1.25% IPBC
  • PRODUCT BASE Screening Emulsion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

What is described herein are antimicrobial compositions which are defined blends of a l,2-diol and pbenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.

Description

ANTIMICROBIAL COMPOSITIONS
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to antimicrobial compositions, and, more particularly, to a defined blend of a 1,2-diol and phenoxyethanol, optionally with a co-biocide, which compositions show broad activity against bacteria, fungi and mold spores.
2. Description of the Prior Art Personal care products come in many different forms. They include creams, lotions, pastes, liquids, aerosols, shampoos, gels, wipes, bars, sticks, powders and granules any or all of which are intended for topical application to the skin including the scalp and the mucosa including the lips. The products are generally designed to have a substantial shelf life. The products need to be manufactured at one site, transported possibly over a considerable distance to a depot or other storage facility prior to further transport to a point of sale. The product may then spend considerable time on a retailer's shelf prior to purchase and further storage by the user whether for individual use or use in, for example, a hotel, workplace, institution or the like. All of such storage will take place under uncontrolled conditions including considerable variation in temperature. In order to keep bacterial and fungal growth in such products at an acceptable level it is conventional practice for the products to contain a preservative. Many preservatives are available. The appropriate preservative has to be selected with regard to its efficacy and its acceptability to contact with human or animal skin. With regard to its acceptability there are in many countries laws and regulations governing the maximum permitted content of preservative in products intended for human use due to their possible toxic or otherwise harmful effect. The need to control microbiological growth in personal care products is known to be particularly acute in water based products such as non-ionic oil-in-water emulsions and in pre-impregnated wipes such as baby wipes. For example, U.S. Pat. 6,607,738 described a preservative system of iodopropynyl butyl carbamate (IPBC) and phenoxyethanol (PE) in a weight ratio of 1 :90 to 1 :400 for use in personal care products.
U.S. Pat. 5,516,510 also disclosed deodorizing active ingredients to reduce the unpleasant odor caused by microorganisms which comprised a glycerin monoalkyl ether in combination with an astringent and/or a naturally occurring deodorant.
EP 1206933 described a preservative composition of caprylyl glycol (1,2-octanediol) and iodopropynyl butyl carbamate in a weight ratio of 0.1 to 500.
U.S. Pat. 5,733,362 was directed to a bacterial composition of 2-methyl-4,5- trimethylene-4-isothiazoline-3-on; 3-iodo-2-propynyl butyl carbamate and 2-phenoxyethanol .
EP 1238651 described that the activity of preservative mixtures of iodopropynyl butyl carbamate and phenoxyethanol, in a weight ratio of 1 :90 to 1 :200, preferably 1 :100, can be potentiated by adding caprylyl glycol thereto, in a weight ratio of the latter to the mixture of 0.1 to 500, preferably 1 :55. Thus the formulation of caprylyl glycol, iodopropynyl butyl carbamate and phenoxyethanol had weight ratios of each of 55: 1 : 100 to 200:1 :400, respectively. The personal care formulations contained 0.1-30% caprylyl glycol, preferably 0.5%; with 0.001-1% IPBC, preferably 0.001-0.01%; and with phenoxyethanol of 0.1-3%, preferably 0.5-1%.
JP Application No. 11045504 described an antiseptic microbicide and compositions thereof which contained a 1,2-alkane diol. These compositions effectively reduced the required dosage of conventional antiseptic microbicides such as paraben, benzoic acid and the like. The 1,2-alkane diol therein could be blended with a photosensitizer, benzoic acid or its salt, phenoxyethanol or 4-isopropyl-3-methylphenol. However, there was no disclosure of suitable blends of 1,2-alkane diol and phenoxyethanol at predetermined weight ratios and HLB values, which could deliver water insoluble biocides such as IPBC into aqueous personal care systems at a relatively high concentration of such biocides.
These and other prior art references in this field were concerned with the problem that many are antibacterials such as IPBC have limited aqueous solubility in personal care systems; particularly at the high concentrations necessary for effective antimicrobial activity. Thus, at very low concentrations they remain in solution but do not contribute as much activity as desired for these products. Accordingly, it is desired to provide a blend of 1 ,2-diol and phenoxyethanol at a predetermined ratio and HLB value which can deliver water insoluble biocides into an aqueous personal care system at relatively high concentrations thereby providing more effective preservative activity in such systems.
SUMMARY OF THE INVENTION What is described herein is an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt. (a) 40-60% of a 1 ,2-diol selected from the group consisting of 1 ,2-pentanediol, 1,2-hexanediol and 1,2-octanediol; (b) 40-60%) of phenoxyethanol; and (c) 0- 10%) of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and
1 ,2-benzisothiazolin-3-one. A preferred antimicrobial composition of the invention includes (c) sorbic acid and/or 1 % iodopropynyl butyl carbamate. Most preferred antimicrobial compositions herein are those wherein (a) is about 44% and (b) is about 56%. Also preferred are antimicrobial compositions wherein (c) is sorbic acid present in an amount of about 5-7% of the composition, or IPBC present in an amount of 1.25-1.50%. Preferred antimicrobial compositions of the invention include those wherein (a) is 41-42%), (b) is 52-53%; and (c) is sorbic acid 5-7%; and (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%. The invention also encompasses personal care products which include the antimicrobial composition described above, preferably wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably 0.5-1.5%.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the invention, there is provided herein an antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt. (a) 40-60% of a 1,2-diol selected from the group consisting of 1 ,2-pentanediol, 1 ,2-hexanediol and 1,2-octanediol; (b) 40-60%) of phenoxyethanol; and (c) 0-10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and
1 ,2-benzisothiazolin-3-one. Preferably the antimicrobial composition includes (c) sorbic acid and/or 1% iodopropynyl butyl carbamate.
Most preferably, the antimicrobial composition includes (a) about 44% and (b) about 56%, and, optionally, (c) is sorbic acid, present in an amount of about 5-7% of the composition, or (c) is IPBC present in an amount of 1.25-1.50%.
Most preferably, it is an antimicrobial composition wherein (a) is 41-42%, (b) is 52-53%>; and (c) is sorbic acid 5-7%; most preferably, wherein (a) is 43.3; (b) is 55.3; and (c) is IPBC 1.4%.
Personal care products particularly utilize the antimicrobial composition, preferably, wherein the antibacterial composition is present in an amount of 0.1-2% by weight of the product, most preferably, 0.5-1.5%). The invention will now be described in more detail by the following challenge test examples on the invention formulations.
EXAMPLE 1 ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60 wt. ratio) PRODUCT BASE: Screening emulsion (Standard Emulsion)
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 1.9x10° cfu/ml 1.2x10° cfu/ml
E. coli 8739 4.6x106 cfu/ml 2. lxl 06 cfu/ml
P. aeruginosa 9027 1.7x106 cfu/ml 2.1xl06 cfu/ml
B. cepacia 25416 2.5x106 cfu/ml 2.0x106 cfu/ml
C. albicans 10231 2.7x106 cfu/ml 9.0x105 cfu/ml A. niger 16404 3.0xl05 cfu/ml 1.0x105 cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph.aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 2.2E5 <10 <10 <10 <10
A. niger 16404 5.5E5 2E4 3.8E2 6E1 6.6E3
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph.aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 1.4E5 <10 <10 <10 <10 EXAMPLE 2
ANTIMICROBIAL:! ,2-Octanediol/Phenoxyethanol (40/60) PRODUCT BASE: Nonionic emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 1.3x10° cfu/ml 8.0x10° cfu/ml
E. coli 8739 3.9x10° cfu/ml 4.8x106 cfu/ml
P. aeruginosa 9027 2.5x106 cfu/ml 4.7x10° cfu/ml
B. cepacia 25416 1.5x106 cfu/ml 1. Ox 106 cfu/ml
C. albicans 10231 3.2xl06cfu/ml 1.6x106 cfu/ml A. niger 16404 4.0x105 cfu/ml 2.6x105 cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 1.4E5 <10 <10 <10 <10
E. coli 8739 6.6E3 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 4.0E4 <10 <10 <10 <10
C. albicans 10231 >1E6 8.1E5 5.2E4 <10 >1E4
A. niger 16404 5.9E5 1.9E5 3.5E4 1.2E4 6.9E5
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 3.4E5 <10 <10 <10 <10 A. niger 16404 6.5E5 2.4E4 1.2E3 9E1 >1E4 EXAMPLE 3
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 4.9x10° cfu/ml 2.6x10° cfu/ml
E. coli 8739 5.6xl06 cfu/ml 4.3x106 cfu/ml
P. aeruginosa 9027 3.1xl06 cfu/ml 3.2x10° cfu/ml
B. cepacia 25416 2.7x106 cfu/ml 1.8x106 cfu/ml
C. albicans 10231 4.2x106 cfu/ml 1.7x107 cfu/ml A. niger 16404 1.9xl05cfu/ml 4.0x105 cfu/ml
USE LEVEL: 0.67% (100 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10
USE LEVEL: 1.33% (200 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10 EXAMPLE 4
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 1.2xl06cfu/ml 3.7x10° cfu/ml
E. coli 8739 3.2xl06 cfu/ml 3.1xl06cfu/ml
P. aeruginosa 9027 3.0xl06 cfu/ml 4.6x106 cfu/ml
B. cepacia 25416 6.0x105 cfu/ml 3.2x106 cfu/ml
C. albicans 10231 2.8x106 cfu/ml 2.4x106 cfu/mml A. niger 16404 7.0x105 cfu/ml 4.0x105 cfu/ml
USE LEVEL: 0.67% (100 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 3E1 <10 <10 <10 <10
USE LEVEL: 1.33% (200 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10 EXAMPLE 5
ANTIMICROBIAL: 1 ,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 3.7xl06cfu/ml 2.9x10° cfu/ml
E. coli 8739 3.1xl06 cfu/ml 5.4x10° cfu/ml
P. aeruginosa 9027 4.6x106 cfu/ml 3.8xl06 cfu/ml
B. cepacia 25416 3.2x106 cfu/ml 2.9x106 cfu/ml
C. albicans 10231 2.4x10° cfu ml 2.2x10° cfu/ml A. niger 16404 4.0x105 cfu/ml 2.9x105 cfu/ml
USE LEVEL: 0.25% (37.5 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 7.1E2 <10 <10 <10 <10
A. niger 16404 4.2E4 3.4E3 1.2E2 2E1 6.7E2
USE LEVEL: 0.5% (75 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 2E1 (replate <10) EXAMPLE 6
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 4.9x10° cfu/ml 4.8x10° cfu/ml
E. coli 8739 3.5xl06cfu/ml 3. lxlO6 cfu/ml
P. aeruginosa 9027 4.0x106 cfu/ml 3.0x106 cfu/ml
B. cepacia 25416 4.0xl06 cfu/ml 2.2x106 cfu/ml
C. albicans 10231 3.5xl06 cfu/ml 8.0x105 cfu/ml A. niger 16404 2.7x10° cfu/ml 1.8x105 cfu/ml
USE LEVEL: 0.25% (37.5 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 2E1 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 2E1 <10 <10 <10 <10
C. albicans 10231 >1E6 7.2E2 1E2 <10 >1E4
A. niger 16404 3.9E5 2.4E5 1.9E5 1.6E5 2.5E5
USE LEVEL: 0.50% (75 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 4.4E4 2E3 5E1 <10 3.5E3 EXAMPLE 7
ANTIMICROBIAL: 1 ,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 3.6x10° cfu/ml 2.8x10° cfu/ml
E. coli 8739 5.8x106 cfu/ml 3.5x106 cfu/ml
P. aeruginosa 9027 4.0x106 cfu/ml 3.2xl06 cfu/ml
B. cepacia 25416 3.0xl06 cfu/ml 1.8x106 cfu/ml
C. albicans 10231 2.7xl06 cfu/ml 1.7xl06 cfu/ml A. niger 16404 1.3x106 cfu/ml 4.9x105 cfu/ml
USE LEVEL: 0.50% (75 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10
USE LEVEL: 0.67% (100 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10 EXAMPLE 8
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60) / 2.5% BIT
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 3.6x10° cfu/ml 2.8x10° cfu/ml
E. coli 8739 5.8x106 cfu/ml 3.5x10° cfu/ml
P. aeruginosa 9027 4.0x106 cfu/mml 3.2x106 cfu/ml
B. cepacia 25416 3.0x106 cfu/ml 1.8x106 cfu/ml
C. albicans 10231 2.7x106 cfu/ml 1.7x106 cfu/ml A. niger 16404 1.3x106 cfu/ml 4.9x105 cfu/ml
USE LEVEL: 0.3% (75 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 5.8E3 2E1 <10 <10 <10
A. niger 16404 1.8E2 <10 <10 <10 <10
USE LEVEL: 0.4% (100 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10 EXAMPLE 9
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60) / 1.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 3.0x10° cfu/ml 2.8x10° cfu/ml
E. coli 8739 5.8xl06 cfu/ml 3.5x10° cfu/ml
P. aeruginosa 9027 4.0xl06 cfu/ml 3.2xl06 cfu/ml
B. cepacia 25416 3.0x106 cfu/ml 1.8x106 cfu/ml
C. albicans 10231 2.7x106 cfu/ml 1.7x106 cfu/ml A. niger 16404 1.3x106 cfu/ml 4.9x105 cfu/ml
USE LEVEL: 0.50% (75 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 8E1 <10 <10 <10 <10
USE LEVEL: 0.67% (100 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10 EXAMPLE 10
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60) / 2.5% BIT
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 3.0x10° cfu/ml 2.8x10° cfu/ml
E. coli 8739 5.8xl06 cfu/ml 3.5xl06 cfu/ml
P. aeruginosa 9027 4.0x10° cfu/ml 3.2xl06 cfu/ml
B. cepacia 25416 3.0xl06 cfu/ml 1.8x106 cfu/ml
C. albicans 10231 2.7x106 cfu/ml 1.7x106 cfu/ml A. niger 16404 1.3x10° cfu/ml 4.9x105 cfu/ml
USE LEVEL: 0.30% (75 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 1E4 8.6E2 2.1E2 3E1 8.3E2
USE LEVEL: 0.40% (100 ppm BIT) ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 1E1 <10 <10 <10 <10 EXAMPLE 11
ANTIMICROBIAL : 1,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 1.3x10° cfu/ml 8.0x10° cfu/ml
E. coli 8739 3.9xl06 cfu/ml 4.8x106 cfu/ml
P. aeruginosa 9027 2.5x10° cfu/ml 4.7x106 cfu/ml
B. cepacia 25416 1.5x106 cfu/ml 1.0x106 cfu/ml
C. albicans 10231 3.2x10° cfu/ml 1.6x106 cfu/ml A. niger 16404 4.0x105 cfu/ml 2.6x105cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 1.1E2 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 8E3 7E4 1.1E5
C. albicans 10231 >1E6 3.1E4 <10 <10 >1E4
A. niger 16404 8.3E5 4E1 <10 <10 1E1
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 1.2E4 <10 <10 <10 <10
A. niger 16404 3E5 <10 <10 <10 <10 EXAMPLE 12
ANTIMICROBIAL : 1,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 6.9x10° cfu/ml 1.8x10° cfu/ml
E. coli 8739 7.8x10° cfu/ml 3.5x106 cfu/ml
P. aeruginosa 9027 5.1xl06cfu/ml 1.3x106 cfu/ml
B. cepacia 25416 2.2x10° cfu/ml 7.0xl06 cfu/ml
C. albicans 10231 3.7xl06 cfu/ml 6.0x107 cfu/ml A. niger 16404 1.8x105 cfu/ml 8.0xl05 cfu/ml
USE LEVEL: 0.50% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 1E1 <10 <10 <10 <10
E. coli 8739 6E1 <10 <10 <10 <10
P. aeruginosa 9027 1E2 <10 <10 <10 <10
B. cepacia 25416 5.8E4 <10 <10 <10 <10
C. albicans 10231 >1E6 1.7E5 2E1 <10 >1E4
A. niger 16404 1E5 5.8E4 3E4 6E3 3.9E5
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 3E4 <10 <10 <10 <10 EXAMPLE 13
ANTIMICROBIAL: 1 ,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 6.9x10° cfu/ml 1.8x10° cfu/ml
E. coli 8739 7.8x106 cfu/ml 3.5xl06 cfu/ml
P. aeruginosa 9027 5.1xl06cfu/ml 1.3x106 cfu/ml
B. cepacia 25416 2.2x106 cfu/ml 7.0x106 cfu/ml
C. albicans 10231 3.7xl06 cfu ml 6.0x107 cfu ml A. niger 16404 1.8xl05 cfu/ml 8.0x105 cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 8E1 <10 <10 <10 2E1
C. albicans 10231 >1E6 1.4E4 <10 <10 <10
A. niger 16404 2.1E5 5.5E4 8E3 3E3 3.4E5
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 8E3 <10 <10 <10 <10 EXAMPLE 14
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60), 6% sorbic acid
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 6.9x10° cfu/ml 1.8x106 cfu/ml
E. coli 8739 7.8x106 cfu/ml 3.5x106 cfu/ml
P. aeruginosa 9027 5.1xl06cfu/ml 1.3x106 cfu/ml
B. cepacia 25416 2.2x106 cfu/ml 7.0x106 cfu/ml
C. albicans 10231 3.7x106 cfu/ml 6.0x107 cfu/ml A. niger 16404 1.8x105 cfu/ml 8.0xl05 cfu/ml
USE LEVEL: 0.50% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 >1E6 2E4 <10 <10 >1E4
A. niger 16404 1.8E5 1.1E5 1.2E3 2E2 >1E4
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 6E3 <10 <10 <10 7E1 EXAMPLE 15
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60)
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 2.9x10° cfu/ml 2.5x105 cfu/ml
E. coli 8739 4.7x106 cfu/ml 3.4xl06 cfu/ml
P. aeruginosa 9027 4.9x106 cfu/ml 1.2x10° cfu/ml
B. cepacia 25416 5.3x10° cfu/ml l.lxlO6 cfu/ml
C. albicans 10231 1.0x106 cfu/ml 1.1x10° cfu/ml A. niger 16404 7.0x105 cfu/ml 4.4x105 cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 7E1 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 4E4 <10 <10 <10 1E1
A. niger 16404 2.3E5 2.3E4 2.5E2 2E1 >1E4
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <.10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 3E4 <10 <10 <10 <10 EXAMPLE 16
ANTIMICROBIAL: 20 Pentanediol/ 20 Hexanediol/ 20 Octanediol/ 40 Phenoxyethanol
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 2.5x10° cfu/ml 2.5x10° cfu/ml
E. coli 8739 6.0x106 cfu/ml 2.9x106 cfu/ml
P. aeruginosa 9027 5.7x10° cfu/ml 2.3x106 cfu/ml
B. cepacia 25416 3.4x10° cfu/ml 1.5x106 cfu/ml
C. albicans 10231 2.9x106 cfu/ml l.lxl06 cfu/mkl A. niger 16404 5. lxlO5 cfu/ml 2.8x10s cfu/ml
USE LEVEL: 0.25% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 1.1E6 1.6E3 <10 <10 >1E4
E. coli 8739 2E2 <10 <10 <10 <10
P. aeruginosa 9027 3E1 3E3 4E1 1E2 >1E4
B. cepacia 25416 >1E6 >1E6 4.3E5 1.8E5 >1E6
C. albicans 10231 7.9E5 1.2E5 4.1E2 2.2E2 >1E4
A. niger 16404 1.8E5 3.2E5 3.3E5 1.4E5 5.1E5
USE LEVEL: 0.50% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 9.8E4 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 2.7E5 <10 <10 <10 <10
C. albicans 10231 3.8E5 2E2 <10 <10 8E1
A. niger 16404 2.6E5 3.3E5 1.7E3 8E2 >1E EXAMPLE 17
ANTIMICROBIAL: 20 Pentanediol/ 20 Hexanediol/ 20 Octanediol/40 Phenoxyethanol
PRODUCT BASE: Nonionic Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 2.5x10° cfu/ml 2.5x10° cfu/ml
E. coli 8739 6.0x106 cfu/ml 2.9x106 cfu/ml
P. aeruginosa 9027 5.7x106 cfu/ml 2.3x10° cfu/ml
B. cepacia 25416 3.4x106 cfu/ml 1.5x106 cfu/ml
C. albicans 10231 2.9x10° cfu/ml l.lxl06 cfu/mkl A. niger 16404 5.1xl05 cfu/ml 2.8x105 cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 2.6E5 <10 <10 <10 <10
E. coli 8739 2.2E4 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 2.6E5 6E3 <10 <10 2.9E3
C. albicans 10231 >1E6 >1E6 4.8E4 7.1E2 9.3E5
A. niger 16404 6.8E5 4.8E5 1.4E5 >1E4 6.2E5
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 1E2 <10 <10 <10 <10
C. albicans 10231 >1E6 2.8E4 <10 <10 <10 A. niger 16404 3.8E5 3.5E5 1.3E4 2.9E2 5.3E4 EXAMPLE 18
ANTIMICROBIAL: 20 Pentanediol/ 20 Hexanediol/ 20 Octanediol/40 Phenoxyethanol
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 1.8x10° cfu/ml 1.0x10° cfu/ml
E. coli 8739 3.5x106 cfu/ml 3.6x10° cfu/ml
P. aeruginosa 9027 1.3x106 cfu/ml 2.9x106 cfu/ml
B. cepacia 25416 7.0x10° cfu/ml 3.0xl06 cfu/ml
C. albicans 10231 6.0x105 cfu/ml 2.1xl06 cfu/ml A. niger 16404 8.0x105 cfu/ml 2.8x105 cfu/ml
USE LEVEL: 0.5% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 1.3E4 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 1.9E5 <10 <10 <10 <10
C. albicans 10231 3E5 3.3E3 <10 <10 9.7E2
A. niger 16404 6.8E5 6E4 3.3E4 1.1E4 6E4
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 3.8E2 <10 <10 <10 <10 A. niger 16404 4.9E4 1.4E4 1.7E2 1.3E2 6.7E3 EXAMPLE 19
ANTIMICROBIAL: 1,2-Octanediol/Phenoxyethanol (40/60), 1.25% IPBC
PRODUCT BASE: Screening Emulsion
TEST ORGANISMS INOCULUM (0 hours) REINOCULUM (21 days)
Staph aureus 6538 3.6x10° cfu/ml 1.6x10° cfu/ml
E. coli 8739 4.0xl06 cfu/ml 2.2x106 cfu/ml
P. aeruginosa 9027 4.4x10° cfu/ml 1.7x106 cfu/ml
B. cepacia 25416 3.0x10° cfu/ml 1.7x10° cfu/ml
C. albicans 10231 4.2x106 cfu/ml 9.3x105 cfu/ml A. niger 16404 9.0x105 cfu/ml 2.6x105 cfu/ml
USE LEVEL: 1.0% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10
USE LEVEL: 1.8% ASSAY INTERVALS
TEST ORGANISMS 48 HRS 7 D 14D 21D 28D
Staph. aureus 6538 <10 <10 <10 <10 <10
E. coli 8739 <10 <10 <10 <10 <10
P. aeruginosa 9027 <10 <10 <10 <10 <10
B. cepacia 25416 <10 <10 <10 <10 <10
C. albicans 10231 <10 <10 <10 <10 <10
A. niger 16404 <10 <10 <10 <10 <10

Claims

WHAT IS CLAIMED IS:
1. An antimicrobial composition which is active against bacteria, yeast and mold spores, consisting essentially of, by wt. (a) 40-60% of a 1 ,2-diol, and selected from the group consisting of 1 ,2-pentanediol, 1 ,2-hexanediol and 1,2-octanediol; (b) 40-60% of a phenoxyethanol; and (c) 0- 10% of a co-biocide selected from the group consisting of sorbic acid, benzoic acid, dibromodicyanobutane, iodopropynyl butyl carbamate and
1 ,2-benzisothiazolin-3-one.
2. An antimicrobial composition according to claim 1 in which (c) is sorbic acid and/or 1% iodopropynyl butyl carbamate.
3. An antimicrobial composition according to claim 1 wherein (a) is about 44% and (b) is about 56%.
4. An antimicrobial composition wherein (c) is sorbic acid, present in an amount of about 5-7% of the composition.
5. An antimicrobial composition of claim 1 wherein (c) is iodopropynyl butyl carbamate present in an amount of 1.25-1.50%.
6. An antimicrobial composition of claim 1 wherein (a) is 41-42%, (b) is 52-53%; and (c) is sorbic acid of 5-7%.
7. An antimicrobial composition of claim 1 wherein (a) is 43.3; (b) is 55.3; and (c) is iodopropynyl butyl carbamate of 1.4%.
8. A personal care product including the antimicrobial composition of claim 1.
9. A personal care product of claim 1 wherein the antimicrobial composition is present in an amount of 0.1 -2% by weight of the product.
10. A personal care product of claim 1 wherein said amount is 0.5-1.5%.
PCT/US2005/008370 2004-04-08 2005-03-11 Antimicrobial compositions Ceased WO2005102276A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005235136A AU2005235136B2 (en) 2004-04-08 2005-03-11 Antimicrobial compositions
EP05728244.4A EP1734922B1 (en) 2004-04-08 2005-03-11 Antimicrobial compositions
BRPI0509652-9A BRPI0509652B1 (en) 2004-04-08 2005-03-11 ANTIMICROBIAL COMPOSITION AND PERSONAL TREATMENT PRODUCT
JP2007507324A JP2007532542A (en) 2004-04-08 2005-03-11 Antibacterial composition
ES05728244T ES2422897T3 (en) 2004-04-08 2005-03-11 Antimicrobial compositions
CA2560010A CA2560010C (en) 2004-04-08 2005-03-11 Antimicrobial compositions
PL05728244T PL1734922T3 (en) 2004-04-08 2005-03-11 Antimicrobial compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/820,349 2004-04-08
US10/820,349 US7935732B2 (en) 2004-04-08 2004-04-08 Antimicrobial compositions

Publications (1)

Publication Number Publication Date
WO2005102276A1 true WO2005102276A1 (en) 2005-11-03

Family

ID=35061391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008370 Ceased WO2005102276A1 (en) 2004-04-08 2005-03-11 Antimicrobial compositions

Country Status (9)

Country Link
US (2) US7935732B2 (en)
EP (1) EP1734922B1 (en)
JP (1) JP2007532542A (en)
CN (1) CN100508963C (en)
AU (1) AU2005235136B2 (en)
CA (1) CA2560010C (en)
ES (1) ES2422897T3 (en)
PL (1) PL1734922T3 (en)
WO (1) WO2005102276A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1665933A3 (en) * 2004-11-16 2006-08-16 Rohm and Haas Company Microbicidal composition
FR2896123A1 (en) * 2007-02-02 2007-07-20 Clarins Soc Par Actions Simpli SYSTEM FOR PRESERVING A COSMETIC COMPOSITION
WO2008071027A1 (en) * 2006-12-15 2008-06-19 Givaudan Sa Compositions
JP2010535254A (en) * 2007-08-02 2010-11-18 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド Phosphate esters containing phosphorus atoms bridged through diol units
EP2272339A3 (en) * 2009-06-15 2012-10-03 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
EP2589291A1 (en) * 2011-11-04 2013-05-08 Symrise AG Synergistically active ternary anti-microbial mixtures
US8933134B2 (en) 2010-06-09 2015-01-13 L'oreal Compositions containing agar and a softening agent
US10674722B2 (en) 2012-02-24 2020-06-09 Gojo Industries, Inc. Antimicrobial and foamable alcoholic compositions
EP3288380B1 (en) 2015-04-09 2021-11-24 ISP Investments LLC Synergistic preservative compositions
US11628129B2 (en) 2017-04-04 2023-04-18 Gojo Industries, Inc. Methods and compounds for increasing virucidal efficacy in hydroalcoholic systems

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935732B2 (en) * 2004-04-08 2011-05-03 Isp Investments Inc. Antimicrobial compositions
US7854940B2 (en) * 2004-09-16 2010-12-21 Arch Chemicals, Inc. Broad spectrum preservation blends
US20080139672A1 (en) * 2006-02-14 2008-06-12 Playtex Products, Inc. Synergistic preservative systems and their use in cosmetic compositions
US20070190005A1 (en) * 2006-02-14 2007-08-16 Playtex Products, Inc. Synergistic preservative systems and their use in cosmetic compositions
WO2007098135A2 (en) * 2006-02-21 2007-08-30 Inolex Investment Corporation Anti-microbial compositions
DE102007036187A1 (en) * 2007-08-02 2008-06-19 Clariant International Limited Alkoxylated phosphoric acid triesters with a high degree of alkoxylation
ES2582555T3 (en) * 2007-11-29 2016-09-13 Inolex Investment Corporation Preservatives for cosmetic, toilet and pharmaceutical compositions
US20090227675A1 (en) * 2008-03-07 2009-09-10 Susan Lindstrom Antimicrobial Compositions
EP2153813A1 (en) * 2008-08-15 2010-02-17 Lonza, Inc. Synergistic preservative blends
WO2008119841A2 (en) * 2008-07-10 2008-10-09 Symrise Gmbh & Co. Kg Compositions comprising benzyl alcohol derivatives and further antimicrobial active compounds
FR2940281B1 (en) 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique ESTER OF DIOL AND POLYUNSATURATED FATTY ACID AS ANTI-ACNE AGENT
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
JP5210360B2 (en) * 2009-07-30 2013-06-12 ローム アンド ハース カンパニー Synergistic microbicidal composition
US20130101530A1 (en) * 2011-10-25 2013-04-25 Galaxy Surfactants Ltd. Antimicrobial preservative compositions for personal care products
DE102013222164A1 (en) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilized multiple emulsions as a skin protection product
US11737961B2 (en) 2014-03-25 2023-08-29 Basf Se Preservation mixtures, and polymer solutions stabilized therewith
CN107072191A (en) * 2014-09-09 2017-08-18 海德罗默公司 Antimicrobial soap containing carvacrol and use its method
RU2580621C1 (en) * 2014-11-24 2016-04-10 Ирина Юрьевна Журавлева Biocidal composition for aseptic storage of preserved prosthetic material from tissues of animal origin
US11634666B2 (en) * 2015-12-22 2023-04-25 3M Innovative Properties Company Methods for spore removal comprising a polysorbate surfactant and cationic antimicrobial mixture
CN109563454A (en) * 2016-06-22 2019-04-02 伦萨公司 Antiseptic composition for wet wipe
EP3520785B1 (en) * 2016-10-09 2024-07-17 Shenzhen Eulikan Biotechnology Co., Ltd. Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use
JP7060357B2 (en) * 2017-10-30 2022-04-26 花王株式会社 Moldicide composition
JP2020063363A (en) * 2018-10-17 2020-04-23 三菱鉛筆株式会社 Aqueous ink composition for writing instrument
WO2022122137A1 (en) * 2020-12-09 2022-06-16 Symrise Ag Compositions comprising antimicrobials and (bio)-alkanediols for skin protection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733362A (en) * 1995-12-08 1998-03-31 Troy Corporation Synergistic bactericide
JPH11322591A (en) * 1998-02-24 1999-11-24 Mandom Corp Antiseptic disinfectant and composition for human application
US6607738B2 (en) * 1997-04-24 2003-08-19 Nipa Laboratories, Ltd. Chemical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102412D0 (en) * 1991-02-05 1991-03-20 Ici Plc Composition
DE4240674C2 (en) * 1992-11-26 1999-06-24 Schuelke & Mayr Gmbh Deodorant ingredients
US5428050A (en) * 1994-04-28 1995-06-27 Isp Chemicals Inc. Synergistic water soluble preservative compositions of biocidal mixtures
JP3657395B2 (en) * 1996-05-27 2005-06-08 株式会社資生堂 Composition for external use
EP1206933B1 (en) * 2000-11-16 2006-05-17 Johnson & Johnson Consumer France SAS Compositions comprising caprylyl glycol and iodopropynyl butylcarbamate
DE60206433T2 (en) * 2001-02-27 2006-07-20 Johnson & Johnson Consumer France Sas Agents to potentiate the effectiveness of preservatives in sunscreen formulations
JP2003286153A (en) * 2002-01-24 2003-10-07 Shiseido Co Ltd Skin care composition
DE10206759A1 (en) * 2002-02-19 2003-08-28 Dragoco Gerberding Co Ag Use of 1,2-alkanediol mixture as an antimicrobial agent, e.g. for treating body odor, acne or mycoses or preserving perishable products
FR2838346A1 (en) * 2002-09-09 2003-10-17 Oreal Cosmetic or dermatological composition useful for skin cleansing and/or care comprises a haloalkynyl carbamate and caprylyl glycol
US20040152749A1 (en) * 2003-02-04 2004-08-05 Isp Investments Inc. Antimicrobial oxazolidine/iodopropynyl-butyl carbamate composition containing less than 0.1 wt%free formaldehyde
US7935732B2 (en) * 2004-04-08 2011-05-03 Isp Investments Inc. Antimicrobial compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733362A (en) * 1995-12-08 1998-03-31 Troy Corporation Synergistic bactericide
US6607738B2 (en) * 1997-04-24 2003-08-19 Nipa Laboratories, Ltd. Chemical composition
JPH11322591A (en) * 1998-02-24 1999-11-24 Mandom Corp Antiseptic disinfectant and composition for human application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1734922A1 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311320A3 (en) * 2004-11-16 2011-10-26 Rohm and Haas Company Microbicidal composition
EP2289334A3 (en) * 2004-11-16 2011-11-02 Rohm and Haas Company Microbicidal composition
EP1665933A3 (en) * 2004-11-16 2006-08-16 Rohm and Haas Company Microbicidal composition
CN101557707B (en) * 2006-12-15 2013-09-25 奇华顿股份有限公司 combination
WO2008071027A1 (en) * 2006-12-15 2008-06-19 Givaudan Sa Compositions
CN101557707A (en) * 2006-12-15 2009-10-14 吉万奥丹股份有限公司 Compositions
JP2010512348A (en) * 2006-12-15 2010-04-22 ジボダン エス エー Composition
US9192559B2 (en) 2006-12-15 2015-11-24 Givaudan Sa Compositions
FR2896123A1 (en) * 2007-02-02 2007-07-20 Clarins Soc Par Actions Simpli SYSTEM FOR PRESERVING A COSMETIC COMPOSITION
JP2010535254A (en) * 2007-08-02 2010-11-18 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド Phosphate esters containing phosphorus atoms bridged through diol units
US8686033B2 (en) 2007-08-02 2014-04-01 Clariant Finance (Bvi) Limited Phosphoric acid esters containing phosphorus atoms bridged by diol units
US10271548B2 (en) 2009-06-15 2019-04-30 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
US10130093B2 (en) 2009-06-15 2018-11-20 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
US10285399B2 (en) 2009-06-15 2019-05-14 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
US10278388B2 (en) 2009-06-15 2019-05-07 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
EP2272339A3 (en) * 2009-06-15 2012-10-03 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
US9402393B2 (en) 2009-06-15 2016-08-02 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
EP2443223A4 (en) * 2009-06-15 2013-12-25 Gojo Ind Inc ANTIMICROBIAL COMPOSITIONS
US10004227B2 (en) 2009-06-15 2018-06-26 Gojo Industries, Inc. Methods and compositions for use with gel dispensers
US8933134B2 (en) 2010-06-09 2015-01-13 L'oreal Compositions containing agar and a softening agent
US9585388B2 (en) 2011-11-04 2017-03-07 Symrise Ag Synergistically acting ternary antimicrobial mixtures
EP2589291B1 (en) 2011-11-04 2016-12-07 Symrise AG Synergistically active ternary anti-microbial mixtures
EP2589291A1 (en) * 2011-11-04 2013-05-08 Symrise AG Synergistically active ternary anti-microbial mixtures
KR20130049729A (en) * 2011-11-04 2013-05-14 시므라이즈 아게 Synergistically acting ternary antimicrobial mixtures
KR102043869B1 (en) * 2011-11-04 2019-11-12 시므라이즈 아게 Synergistically acting ternary antimicrobial mixtures
US10674722B2 (en) 2012-02-24 2020-06-09 Gojo Industries, Inc. Antimicrobial and foamable alcoholic compositions
EP3288380B1 (en) 2015-04-09 2021-11-24 ISP Investments LLC Synergistic preservative compositions
US11628129B2 (en) 2017-04-04 2023-04-18 Gojo Industries, Inc. Methods and compounds for increasing virucidal efficacy in hydroalcoholic systems

Also Published As

Publication number Publication date
CA2560010A1 (en) 2005-11-03
EP1734922B1 (en) 2013-06-12
US20050228032A1 (en) 2005-10-13
JP2007532542A (en) 2007-11-15
PL1734922T3 (en) 2013-11-29
US20110207787A1 (en) 2011-08-25
CN100508963C (en) 2009-07-08
BRPI0509652A (en) 2007-10-09
CA2560010C (en) 2012-12-11
US7935732B2 (en) 2011-05-03
EP1734922A4 (en) 2008-05-14
US8519010B2 (en) 2013-08-27
AU2005235136B2 (en) 2010-11-11
AU2005235136A1 (en) 2005-11-03
ES2422897T3 (en) 2013-09-16
CN1942170A (en) 2007-04-04
EP1734922A1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
US8519010B2 (en) Antimicrobial compositions
US20070207105A1 (en) Anti-microbial compositions
US20130053422A1 (en) Antimicrobial Compositions
KR101189344B1 (en) Self-preserving skin care formulation
EP0977539B1 (en) Preservative composition comprising iodopropynyl butyl carbamate and phenoxyethanol
KR102405175B1 (en) Antiseptic system with antiseptic synergistic effect
JP2011074082A (en) Antiseptic sterilizer and composition for application to human body
US20090227675A1 (en) Antimicrobial Compositions
ES2875543T3 (en) Antimicrobial mixture containing 4- (3-ethoxy-4-hydroxyphenyl) butan-2-one and an aromatic alcohol, and cosmetic composition containing it
KR20160044071A (en) Preservative composition containing methyl 3-acetyl-4-hydroxybenzoate as an active ingredient
ES2873839T3 (en) Antimicrobial mixture containing 4- (3-ethoxy-4-hydroxyphenyl) butan-2-one and a diol, and cosmetic composition containing the same
EP3195851A1 (en) Composition containing meso-2,3-butanediol
JP4734293B2 (en) Antiseptic disinfectant and human body composition
EP3110254B1 (en) Biocidal mixture compositions and uses thereof
EP1860946B1 (en) Isothiazolone-containing preservative with improved effectiveness
WO2019002397A1 (en) Antimicrobial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and an arginate compound, and cosmetic composition containing same
MXPA06011399A (en) Antimicrobial compositions
KR102189174B1 (en) Composition of antibacterial agent containing industrial preservatives
BRPI0509652B1 (en) ANTIMICROBIAL COMPOSITION AND PERSONAL TREATMENT PRODUCT
HK1024167B (en) Preservative composition comprising iodopropynyl butyl carbamate and phenoxyethanol
IL132493A (en) Chemical composition comprising a preservative system comprising iodopropynyl butyl carbamate and phenoxyethanol and a method for the preparation thereof
HU209802B (en) Deodorant composition with increased effect

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2560010

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005235136

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011399

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007507324

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580011975.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005235136

Country of ref document: AU

Date of ref document: 20050311

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005235136

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005728244

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005728244

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0509652

Country of ref document: BR